spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  adefovir 

 HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Oct 2010
U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jan 2010
Ligand Completes Acquisition of Metabasis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Oct 2009
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Apr 2009
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Biopharmaceuticals
 HSMN NewsFeed - 11 Aug 2008
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Apr 2008
European Commission Approves Viread(R) for Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Nov 2007
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
Biopharmaceuticals
 HSMN NewsFeed - 25 Jun 2007
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2007
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2007
Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Feb 2007
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Jan 2007
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2007
Valeant Pharmaceuticals & Metabasis Therapeutics Close Licensing Deal with Schering-Plough Corporation
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Dec 2006
Valeant Pharmaceuticals and Metabasis Therapeutics License Rights to Hepatitis B Compound Pradefovir to Schering-Plough Corporation
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Dec 2006
Schering-Plough Licenses Worldwide Rights to Pradefovir, Oral Hepatitis B Treatment In Development With Valeant Pharmaceuticals and Metabasis Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 30 Oct 2006
Study Shows Treatment with BARACLUDE(R) (Entecavir) Resulted in Greater Viral Load Reductions Compared to Adefovir in Antiviral Naive Chronic Hepatitis B E-Antigen Positive Patients
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
adefovir
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.